page contents
Photo by JESHOOTS.com on Pexels.com

Proteostasis Therapeutics Stock Price Skyrockets From Positive FDA Phase 1 Results

Proteostasis Therapeutics Announces Positive Preliminary FDA Phase 1 Results

(By Glenford S Robinson)

Proteostasis Therapeutics, Inc. (NASDAQ: PTI), stock price skyrocketed 300% today, October 18, 2017 on positive Phase 1 study news from the Food and Drug Administration (FDA), which stated that the company’s proprietary doublet PTI-801 and PTI-808 cystic fibrosis research medicines have proven safe at the dosage level administered to research volunteers. The study volunteers consist of 20 to 100 individuals, which includes healthy people and those with the disease.

Proteostasis Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company focused on developing therapies effective against cystic fibrosis (CF), a diseased caused by the dysfunctional processing of protein in the human body.

Armed with over 450 issued patents and a topnotch group of research scientists in technology, pharmaceuticals, and healthcare, PTI is confident that it can support its claim as the Inventor of Digital Medicine. In fact, a positive Phase 1 result of its cystic fibrosis research drug study is a strong indication that the company is capable of supporting such claim, as the undisputed Inventor of Digital Medicine.

The company claimed to be the Inventor of Digital Medicine, simply because it has developed a new category of pharmaceuticals that measures the effectiveness of medication treatment, help physicians in improving clinical outcomes and thus, help patients accomplish health goals.

Proteostasis Therapeutics plans to bring its new digital solution to healthcare providers by coordinating its efforts with leading health systems and pharmaceutical companies which will increase access to better insights, optimized therapies, and reduced costs.

© 2018 mstardom.com. Mstardom Finance does not provide investment advice. All rights reserved.

Check Also

Recession Worries Caused Fed to Cut Interest Rate By 25 Basis Points to 1.75 Percent

Even consumers don’t feel all that confident about the economy. The recent Conference Board Consumer Confidence Report for October showed that consumers are less confident about the economy now, than they were a month earlier. The CB Consumer Confidence Report released Tuesday, October 29, 2019, at 10 AM, for October, posted current readings of 125.9 missing forecast of 128.0 and a previous reading of 126.3.

U.S. Economy Stares Recession in the Face, 25 Percent Interest Rate Cut Expected by Fed on Wednesday!

Based on the current New Homes Sales Report, the U.S. economy continues to show slow growth, signaling that the expansion phase, of the business cycle could be coming to an end. The economy began expanding from June 2009, right after the stock market crash of 2008, until now, 11 years later.

U.S. Economy Tip Toeing on Edge of Recession, Retail Sales and Housing Starts Data Show!

If this is not a recession, then I don’t know what is? Can the U.S. economy get any worse than this? Week after week, we continue to get negative economic growth numbers. The GDP hasn’t moved from 2% for the past few months. I know that the classification of a recession is 2 consecutive quarters of negative GDP growth and the classification of a Depression is 8 consecutive quarters of negative GDP growth, but come on!

The Federal Reserve Cut Interest Rate by 25-Basis Points, Wednesday! But Why?

Is the Feds cutting rate because of pressures from President Trump? Or, is the Federal Reserve cutting rate as a result of uncertainties presented by the ongoing trade war between the U.S. and China?

Pre-recession Could be Current State of U.S. Economy, Emotionally!

Defining a recession as two consecutive quarters of negative GDP growth doesn’t tell the whole story of the effect human emotions has on the financial markets. Before there are any consecutive quarters of negative GDP growth, there is the impact of human emotions on the financial markets, which should be taken into consideration. So, by the time two quarters of consecutive GDP growth hits the headlines, investors’ emotions would’ve already nose-dived into depression, dragging down the economy with it. That scenario could be the vampire plaguing the current U.S. economy.

US Interest Rate Cut Sentiment Keeping EUR/USD Above 1.1200

If our prediction holds true, we can expect that the 1.1200 area of support could quickly become an area of resistance all day Thursday, July 25; and may give way Friday a t 8:30 am when US Q2 GDP is expected to come in lower than previous readings.

communication via hand phone

Global Clinical Alarm Management Market to 2023 with Koninklijke Philips, Vocera, Ascom, Spok, Bernoulli, Connexall, Mobile Heartbeat, GE Healthcare, Capsule Technologie & Masimo Dominating

In 2018, North America is expected to account for the largest share of the global clinical alarm management market. The large share of this region can be attributed to the increasing cases of alarm fatigue and initiatives by government bodies to curtail the effects of alarm fatigue and the increasing need for integrated healthcare IT systems to ensure reliability, efficient maintenance of data, data integrity, and timely availability of patient data to authorized healthcare professionals.

%d bloggers like this: